AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMUGENE LTD

0.285

0.000

Volume:1.72M

Turnover:499.59K

Market Cap:82.22M

PE:-0.90

High:0.310

Open:0.300

Low:0.280

Close:0.285

52wk High:2.414

52wk Low:0.245

Shares:288.50M

Float Shares:254.20M

Volume Ratio:0.96

T/O Rate:0.68%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.316

EPS(LYR):-0.316

ROE:-84.54%

ROA:-37.27%

PB:1.83

PE(LYR):-0.90

Loading ...

Overview Company News Filings

Imugene to Seek Shareholder Approval for Capital Consolidation

MT Newswires Live

Imugene Receives Cohort Review Committee Clearance for Phase One Trial Dose Escalation

MT Newswires Live

Why Clover, DroneShield, Imugene, and New Hope shares are racing higher today

ASX Midday Sector Update: Healthcare, Energy Stocks Soar, Utilities Struggle

MT Newswires Live

Wednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025

The Market Herald

BRIEF-Imugene Says Cel Granted FDA Fast Track Designation In Blood Cancer DLBCL

Imugene Obtains US FDA Fast Track Designation for Azer-cel Lymphoma Treatment; Shares Up 6%

MT Newswires Live

Downgraded: Johns Lyng price plunges after disaster repairer gets ASX 200 boot

The Market Herald

BRIEF-Imugene Ltd Appoints Darren Keamy As CFO

Imugene Appoints CFO; Shares Fall 3%

MT Newswires Live

BRIEF-Imugene Posts HY Net Loss Attributable A$48.3 Million

Imugene Receives Patent for Oncolytic Virotherapy Technology in India; Shares Rise 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.285,"timestamp":1756707120000,"preClose":0.285,"halted":0,"volume":1717551,"delay":0,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":288497336,"eps":-0.315594,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-01 16:12:00 AEST","open":0.3,"high":0.31,"low":0.28,"amount":499592,"amplitude":0.105263,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.315594,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1756771200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.285,"openAndCloseTimeList":[[1756684800000,1756706400000]],"volumeRatio":0.9589721731996469,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-37.27%","roe":"-84.54%","lyrEps":-0.315594,"volumeRatio":0.9589721731996469,"shares":288497336,"dividePrice":0,"high":0.31,"amplitude":0.105263,"preClose":0.285,"low":0.28,"week52Low":0.245,"pbRate":"1.83","psRate":"18.70","week52High":2.414,"institutionHeld":0,"latestPrice":0.285,"eps":-0.315594,"divideRate":0,"volume":1717551,"delay":0,"ttmEps":-0.315594,"open":0.3,"prevYearClose":1.258,"prevWeekClose":0.285,"prevMonthClose":0.285,"prevQuarterClose":0.442,"fiveDayClose":0.265,"twentyDayClose":0.3,"sixtyDayClose":0.544},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535153336","title":"Imugene to Seek Shareholder Approval for Capital Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2535153336","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535153336?lang=en_us&edition=fundamental","pubTime":"2025-05-16 12:05","pubTimestamp":1747368343,"startTime":"0","endTime":"0","summary":"Imugene  said it will seek shareholder approval in June for a 34-to-1 share consolidation, reducing its share count from 7.47 billion to about 219.6 million, according to a Friday filing with the Australian bourse.The company said the move is expected to lift the stock's trading price.Shares of the company fell 2% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XKO.AU","BK7067","XAO.AU","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2524424283","title":"Imugene Receives Cohort Review Committee Clearance for Phase One Trial Dose Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524424283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524424283?lang=en_us&edition=fundamental","pubTime":"2025-04-03 09:00","pubTimestamp":1743642007,"startTime":"0","endTime":"0","summary":"Imugene  received clearance from the Cohort Review Committee to escalate the dose level in the intravenous combination segment of its phase one onCARlytics trial, targeting adult patients with advanced or metastatic solid tumors, according to a Thursday Australian bourse filing.The trial seeks to evaluate the safety and efficacy of different routes of administration, intratumoral injection, and intravenous infusion of either onCARlytics, a CD19-expressing oncolytic virus, alone, or in combination with CD19-targeting bispecific monoclonal antibody blinatumomab, which is a cancer immunotherapy.The IV combination arm will progress to a higher dose level after the completion of the safety observation period.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2520941265","title":"Why Clover, DroneShield, Imugene, and New Hope shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2520941265","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520941265?lang=en_us&edition=fundamental","pubTime":"2025-03-19 10:47","pubTimestamp":1742352460,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a subdued session on Wednesday. In afternoon trade, the benchmark index is down 0.2% to 7,844 points. Four ASX shares that are not letting that hold them back ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/19/why-clover-droneshield-imugene-and-new-hope-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7115","HOPE","IMU.AU","DRO.AU","BK7067","BK7036","XJO.AU","BK7508","NHC.AU","CLV.AU","BK7083","BK4211"],"gpt_icon":1},{"id":"2520955399","title":"ASX Midday Sector Update: Healthcare, Energy Stocks Soar, Utilities Struggle","url":"https://stock-news.laohu8.com/highlight/detail?id=2520955399","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520955399?lang=en_us&edition=fundamental","pubTime":"2025-03-19 10:36","pubTimestamp":1742351814,"startTime":"0","endTime":"0","summary":"Healthcare and energy stocks both advanced 0.39% at midday Wednesday. The US Federal Reserve is expected to keep interest rates steady in its monetary policy statement on Wednesday.Imugene  obtained fast-track designation from the US Food and Drug Administration for azer-cel, a potential treatment for relapsed or refractory diffuse large B-cell lymphoma. Azer-cel is in phase 1b clinical trial.On the flip side, the utilities sector struggled, falling 0.95%. The S&P 500, Dow Jones, and Nasdaq composite indices fell in overnight trading and Australian stocks followed them lower.Contact Energy  said its consent application for the proposed Southland Wind Farm project in New Zealand was denied by the Expert Consenting Panel convened under the COVID-19 Recovery Act of 2020.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","HCSG","BK7006","BK4137","IMU.AU","BK7508","CEN.AU"],"gpt_icon":1},{"id":"2520930569","title":"Wednesday’s HotCopper Trends: Imugene scores FDA tick, Arizona kicks off share purchase plan | March 19, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520930569","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520930569?lang=en_us&edition=fundamental","pubTime":"2025-03-19 09:57","pubTimestamp":1742349420,"startTime":"0","endTime":"0","summary":"The ASX has been trading flat at around 7,864 points.Financials has been the best performing sector, up 0.3%, followed by Materials, up 0.15% and Energy, up 0.1%.Utilities has been the worst performer, down 1.1%, followed by Industrials and Staples, both down 0.55%.Opthea  has been the most watched on HotCopper forums today. The company is in a voluntary suspension pending the release of top line results of its COAST clinical trial.Also trending Imugene  has revealed the US Food and Drug Administration has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel , for the treatment of relapsed or refractory diffuse large B-cell lymphoma .Rounding out the most discussed is Arizona Lithium  after kicking off a share purchase plan to raise $2 million to advance the Prairie project.You’re up to date, see you later for market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/wednesdays-hotcopper-trends-imugene-scores-fda-tick-arizona-kicks-off-share-purchase-plan-march-19-2025-2025-03-19/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","OPT.AU","BK7504","BK7067","BK7507","BK7508","IMU.AU","AZL.AU"],"gpt_icon":0},{"id":"2520619909","title":"BRIEF-Imugene Says Cel Granted FDA Fast Track Designation In Blood Cancer DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2520619909","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520619909?lang=en_us&edition=fundamental","pubTime":"2025-03-19 09:15","pubTimestamp":1742346906,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Says Cel Granted FDA Fast Track Designation In Blood Cancer DLBCLMarch 19 (Reuters) - Imugene IMU.AX:AZER-CEL GRANTED FDA FAST TRACK DESIGNATION IN BLOOD CANCER DLBCLFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q11F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2520578469","title":"Imugene Obtains US FDA Fast Track Designation for Azer-cel Lymphoma Treatment; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2520578469","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520578469?lang=en_us&edition=fundamental","pubTime":"2025-03-19 07:41","pubTimestamp":1742341274,"startTime":"0","endTime":"0","summary":"Imugene  obtained fast track designation from the US Food and Drug Administration for azer-cel, a potential treatment for relapsed or refractory diffuse large B-cell lymphoma, according to a Wednesday filing with the Australian bourse.Azer-cel is in phase 1b clinical trial, per the filing.The designation will enable the clinical-stage immuno-oncology company to have more frequent meetings with the US FDA for development plans, the option for a rolling review of regulatory submissions, and potential eligibility for accelerated approval and priority review once relevant criteria are met, the filing stated.The company's shares surged almost 6% in recent Wednesday trade.Price : $0.04, Change: $+0.0020, Percent Change: +5.71%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4567","FAST","IE00BYQQ9H92.USD","BK4585","IMU.AU","IE00BFXG0V08.USD","BK4588","BK4104","BK7508","BK7067","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"2518929645","title":"Downgraded: Johns Lyng price plunges after disaster repairer gets ASX 200 boot","url":"https://stock-news.laohu8.com/highlight/detail?id=2518929645","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518929645?lang=en_us&edition=fundamental","pubTime":"2025-03-10 12:59","pubTimestamp":1741582740,"startTime":"0","endTime":"0","summary":"Johns Lyng Group  has seen a sharp shares selloff through Monday trade after it was confirmed the insurance repairer would be removed from the ASX 200 when the index reshuffles a little later this month.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The ANZ company has lost as much as 12.1% in market value since open, to the tune of -34 cents; Johns Lyng was priced at $2.46 a share just before close.The loss of status comes after Johns Lyng shaved as much as 57% in value in half a year.DigiCo Infrastructure  and Capstone Copper Corp  – which I covered earlier – were among the companies to be added to the 200 index.HotCopper forum darling Imugene  will be dropped from the ASX 300.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/downgraded-johns-lyng-price-plunges-after-disaster-repairer-gets-asx-200-boot-2025-03-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7078","BK7166","BK7055","BK7103","SGR.AU","BK7508","CSC.AU","JLG.AU","PME.AU","IMU.AU","SIG.AU","BK7094","BK7137","BK7110","CKF.AU","DGT.AU"],"gpt_icon":1},{"id":"2516693550","title":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516693550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516693550?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:25","pubTimestamp":1741047942,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO March 4 (Reuters) - Imugene Ltd IMU.AX:APPOINTS DARREN KEAMY AS CFO AND COMPANY SECRETARYMIKE TONROE RESIGNS AS CFOFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2516660815","title":"Imugene Appoints CFO; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516660815","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516660815?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:35","pubTimestamp":1741044931,"startTime":"0","endTime":"0","summary":"Imugene  appointed Clinuvel Pharmaceuticals'  former Chief Financial Officer Darren Keamy as CFO, effective immediately, according to a Tuesday filing with the Australian bourse.Keamy will succeed current CFO Mike Tonroe, the filing said.Shares of the pharmaceutical company fell 3% in recent trade,Price : $0.04, Change: $-0.00100, Percent Change: -2.78%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","XJO.AU","IMU.AU","XKO.AU","XAO.AU","CUV.AU"],"gpt_icon":0},{"id":"2514366878","title":"BRIEF-Imugene Posts HY Net Loss Attributable A$48.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514366878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514366878?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:34","pubTimestamp":1740706449,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Posts HY Net Loss Attributable A$48.3 MillionFeb 28 (Reuters) - Imugene Ltd IMU.AX:HY NET LOSS ATTRIBUTABLE A$48.3 MILLIONFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI29N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2514814255","title":"Imugene Receives Patent for Oncolytic Virotherapy Technology in India; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514814255","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514814255?lang=en_us&edition=fundamental","pubTime":"2025-02-27 10:41","pubTimestamp":1740624075,"startTime":"0","endTime":"0","summary":"Imugene  obtained a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology, according to a Thursday filing with the Australian bourse.The patent is set to expire in 2037. The technology already has intellectual property protection in the US and Japan, the filing said.The clinical-stage immuno-oncology company's shares rose 3% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}]}}